A breakthrough in the staging of neurodegenerative diseases
With age, the prevalence of neurodegenerative disorders such as mild cognitive impairment (MCI), Parkinson's disease, and Alzheimer's Disease continues to increase. Unfortunately, current methods of identifying and tracking cognitive decline are limited and often rely on subjective assessments.
Vistim Labs, a leading healthcare technology company, seeks to change this with their breakthrough CASBATM technology platform, which measures functional cognitive brain activity alongside bio-physiological biomarkers such as amyloid deposits in the brain. This non-invasive, portable, and affordable platform provides a more accurate and sensitive measurement of cognitive decline, enabling early identification and treatment to delay or halt these debilitating disorders.
Presenting CASBA at the 2023 Alzheimer's Disease and Parkinson's Disease International Conference
Vistim Labs presented its revolutionary technology CASBA at the 2023 Alzheimer's Disease and Parkinson's Disease International Conference. In her talk, Dr. Courtnie Paschall revealed new findings demonstrating CASBA's clinical utility for high-precision measurement of disease biomarkers amyloid, tau, and neurodegeneration. All in a single, noninvasive test (n=63).
Often, dementia patients need separate PET, CSF, and MRI procedures for their diagnosis, which can be inconclusive. CASBA's unique ability to measure across necessary endpoints in a single test has changed the game for understanding neuro diseases. Most impressive were preliminary findings showing CASBA's superior accuracy, compared with these other tests, for differentiating individual stages of the disease. Thank you Dr. Courtnie Paschall, James Hamet, and Maxwell Kleinsasser, for bringing these breakthrough results to the greater scientific community and sharing your work at such a prestigious scientific conference.
"We are thrilled to present these groundbreaking results at such a prestigious conference," said Dr. Paschall. "CASBA has the potential to revolutionize how we diagnose and manage neurodegenerative diseases, and we are excited to continue our research in this field."
In addition to the spoken presentation at the ADPD conference, Vistim Labs has been invited to present a poster on CASBA at the Alzheimer's Association International Conference later this year.
Ensuring Timely Treatment and Management of Neurodegenerative Diseases
"Our goal is to help clinicians treat patients more effectively," said James Hamet, CEO of Vistim Labs. "Nothing is more frustrating than ordering a test and receiving inconclusive results. A single, in-office tool to measure across all relevant clinical endpoints is exactly what we need for timely, proper diagnosis and effective intervention."
The Vistim Labs platform represents a significant breakthrough in the early identification and treatment of neurodegenerative disorders. It can help clinicians provide better patient care and earn more revenue at the clinic, with potential to improve millions of lives worldwide.
Vistim Labs is committed to advancing the field of neurodegenerative disease diagnosis and treatment through innovative technology and collaboration. CASBA, their non-invasive, portable, and affordable technology, can revolutionize the world's understanding and management of cognitive decline, enabling early detection and intervention for better patient outcomes. Vistim Labs looks forward to working with its partners in the United States and Europe to validate their technology and bring it to healthcare providers worldwide.
Vistim Labs can be reached through the information below for further information or queries.